Back to Search
Start Over
'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma—A multicentre, retrospective study.
- Source :
- British Journal of Haematology; Aug2023, Vol. 202 Issue 4, p796-800, 5p
- Publication Year :
- 2023
-
Abstract
- Summary: Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co‐morbidities. Here we present data from the first 41 patients treated with 'ACOPP' across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2‐year PFS and OS, 73% (95% CI: 52–94) and 93% (95% CI: 80–100) respectively). [ABSTRACT FROM AUTHOR]
- Subjects :
- HODGKIN'S disease
OLDER patients
CANCER chemotherapy
BLEOMYCIN
PREDNISOLONE
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 202
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 169970988
- Full Text :
- https://doi.org/10.1111/bjh.18947